FDA
-
-
-
-
-
-
-
Regenxbio Inc. (RGNX) PT Lowered to $26 at H.C. Wainwright
-
-
-
-
-
-
-
REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNEĀ® TRIAL OF RGX-202
-
-
-
-
-
-
-
Shareholders that lost money on REGENXBIO Inc.(RGNX) should contact The Gross Law Firm about pending Class Action - RGNX
-
-
-
-
-
-
-
The Gross Law Firm Notifies REGENXBIO Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RGNX
-
-
-
-
-
-
-
Goldman Sachs Reiterates Neutral Rating on Regenxbio Inc. (RGNX)
-
-
-
-
-
-
-
Regenxbio Inc. (RGNX) PT Raised to $45 at Stifel: Lead Programs Have 2026 Catalysts
-
-
-
-
-
-
-
REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITEĀ® Trial of RGX-121 for Treatment of MPS II
-
323,915 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

